NEW YORK, Aug. 11, 2011 /PRNewswire/ -- Venture capital (VC) funding in the Life Sciences sector, which includes the Biotechnology and Medical Device industries, leapt 37 percent during the second quarter of 2011, according to a new PwC US report, "High-dollar deals." The report includes data from the PricewaterhouseCoopers LLP/National Venture Capital Association MoneyTree™ Report, based on data from Thomson Reuters.
Venture capitalists invested $2.1 billion in 206 Life Sciences deals, delivering the seventh best quarter since the MoneyTree Report began collecting data in 1995. Despite the quarter's strong performance, dollars invested in Life Sciences declined 3 percent when compared with the same quarter of 2010. Deal volume also decreased year over year, but by a greater margin of 21 percent. Compared with the first quarter of 2011, deal volume looked more positive, showing an increase of 12 percent.
To read the full, original article click on this link: Life Sciences Venture Capital Investing Leaps 37% in Q2 2011, According to... -- NEW YORK, Aug. 11, 2011 /PRNewswire/ --
